Stratified interventions in ARDS: EMINENT ARDS Work Package 2.

ARDS 的分层干预措施：杰出 ARDS 工作包 2。

• 批准号: MR/X005070/1
• 负责人: Charlotte Summers
• 金额: $ 121.35万
• 依托单位: University of Cambridge
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FX005070%2F1
• 关键词: Stratified; interventions; ARDS; EMINENT; Work

Acute respiratory distress syndrome (ARDS) is a severe form of acute respiratory failure that affects >10% of all patients admitted to intensive care units across the world. Although in-hospital mortality remains high (35-46%), 70% of long-term survivors subsequently return to their pre-morbid employment, indicating significant potential for recovery. There is no licensed pharmacotherapy for ARDS anywhere in the world, and our understanding of ARDS disease processes remains limited. Moreover, considerable heterogeneity exists within the population of patients with ARDS. Together these factors represent a major roadblock to drug discovery. There is an urgent and unmet need to further define disease mechanisms in ARDS, and to develop tools to aid patient stratification so we can ensure the right drug is received by the right patient at the right time.Having identified multiple novel subgroups of patients with ARDS in Work Package One (WP1), we now wish to prospectively validate the presence of these groups in a new population of patients with ARDS, and determine whether the groups we identified are mechanistically discrete, or whether they represent different phases of the same pathology, as well as to determine whether the subgroups we found may be amenable to therapeutic intervention.

急性呼吸窘迫综合征 (ARDS) 是一种严重的急性呼吸衰竭，影响全球重症监护病房所有患者的 10% 以上。尽管院内死亡率仍然很高（35-46%），但 70% 的长期幸存者随后返回病前的工作岗位，这表明康复潜力巨大。世界上任何地方都没有获得许可的 ARDS 药物疗法，我们对 ARDS 疾病过程的了解仍然有限。此外，ARDS 患者群体中存在相当大的异质性。这些因素共同构成了药物发现的主要障碍。目前迫切需要进一步定义 ARDS 的疾病机制，并开发工具来帮助患者分层，以便我们能够确保正确的患者在正确的时间接受正确的药物。在工作包一 (WP1) 中确定了多个新的 ARDS 患者亚组后，我们现在希望前瞻性地验证这些组在新的 ARDS 患者群体中的存在，并确定我们确定的组是否在机制上是离散的，或者它们是否代表不同的阶段 相同的病理学，以及确定我们发现的亚组是否适合治疗干预。

项目成果

Therapeutic potential of IL6R blockade for the treatment of sepsis and sepsis-related death: A Mendelian randomisation study.

• DOI: 10.1371/journal.pmed.1004174
• 发表时间: 2023-01
• 期刊: PLoS medicine
• 影响因子: 15.8

Elevated ferritin, mediated by IL-18 is associated with systemic inflammation and mortality in acute respiratory distress syndrome (ARDS)

• DOI: 10.1136/thorax-2023-220292
• 发表时间: 2023-12-26
• 期刊: THORAX
• 影响因子: 10
• 作者: Mehta，Puja;Samanta，Romit J.;O'Kane，Cecilia M.
• 通讯作者: O'Kane，Cecilia M.

Treating intrusive memories after trauma in healthcare workers: a Bayesian adaptive randomised trial developing an imagery-competing task intervention

治疗医护人员创伤后的侵入性记忆：一项贝叶斯自适应随机试验开发图像竞争任务干预

• DOI: 10.17863/cam.90416
• 发表时间: 2022
• 作者: Ramineni V

Reduced circulating BMP9 and pBMP10 in hospitalized COVID-19 patients.

• DOI: 10.1002/pul2.12192
• 发表时间: 2023-01
• 期刊: PULMONARY CIRCULATION
• 影响因子: 2.6
• 作者: Dunmore, Benjamin J.;Upton, Paul D.;Auckland, Kate;Samanta, Romit J.;Lyons, Paul A.;Smith, Kenneth G. C.;Graf, Stefan W.;Summers, Charlotte;Morrell, Nicholas
• 通讯作者: Morrell, Nicholas

Therapeutic potential of IL6R blockade for the treatment of sepsis and sepsis-related death: a Mendelian randomisation study

IL6R 阻断治疗脓毒症和脓毒症相关死亡的治疗潜力：孟德尔随机研究

• DOI: 10.17863/cam.92642
• 发表时间: 2023
• 作者: Hamilton F